Cronos Group (CRON) to Release Quarterly Earnings on Thursday

Cronos Group (NASDAQ:CRON) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Cronos Group to post earnings of $0.01 per share and revenue of $38.5060 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Cronos Group Stock Up 3.8%

Shares of CRON stock opened at $2.74 on Wednesday. Cronos Group has a 52 week low of $1.60 and a 52 week high of $3.43. The firm has a market capitalization of $1.04 billion, a PE ratio of 27.40 and a beta of 0.80. The company has a 50 day moving average price of $2.67 and a 200-day moving average price of $2.60.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Canaccord Genuity Group started coverage on Cronos Group in a report on Tuesday, January 27th. They set a “buy” rating for the company. Sanford C. Bernstein reissued a “market perform” rating and issued a $2.30 target price on shares of Cronos Group in a report on Wednesday, January 14th. Wall Street Zen raised Cronos Group from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Zacks Research cut Cronos Group from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Cronos Group in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $2.30.

Institutional Investors Weigh In On Cronos Group

A number of institutional investors and hedge funds have recently modified their holdings of CRON. Arrowstreet Capital Limited Partnership increased its holdings in shares of Cronos Group by 192.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 89,683 shares of the company’s stock valued at $171,000 after purchasing an additional 59,013 shares in the last quarter. Virtu Financial LLC raised its holdings in shares of Cronos Group by 10.4% during the fourth quarter. Virtu Financial LLC now owns 52,852 shares of the company’s stock valued at $139,000 after acquiring an additional 4,990 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in Cronos Group by 291.6% in the 1st quarter. Jones Financial Companies Lllp now owns 65,099 shares of the company’s stock valued at $118,000 after purchasing an additional 48,476 shares in the last quarter. Bank of Montreal Can purchased a new stake in Cronos Group during the 4th quarter valued at about $116,000. Finally, CIBC Asset Management Inc acquired a new stake in shares of Cronos Group in the fourth quarter valued at approximately $72,000. Institutional investors and hedge funds own 8.71% of the company’s stock.

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.